Alvotech outlines 2026 revenue target of $650M-$700M while expanding global biosimilar launches
Source: SeekingAlpha
2026-03-19 15:13:27 ET
More on Alvotech
- Alvotech (ALVO) Q4 2025 Earnings Call Transcript
- Alvotech 2025 Q4 - Results - Earnings Call Presentation
- Alvotech: Why FDA Delays Don't Break The Bull Case
- Quant snapshot: Micron, Babcock & Wilcox lead strong buys as Fold Holdings, Alvotech lag
- Alvotech higher on positive data backing biosimilar to Takeda’s Entyvio
Read the full article on Seeking Alpha
For further details see:
Alvotech outlines 2026 revenue target of $650M-$700M while expanding global biosimilar launches
Alvotech
NASDAQ: ALVO
ALVO Trading
2.99% G/L:
$3.445 Last:
85,023 Volume:
$3.35 Open:
ALVO Latest News
ALVO Stock Data
$1,569,389,520
107,654,085
N/A
30
N/A
Pharmaceuticals
Healthcare
LU
Luxembourg
